[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ITRM20040346A1 - Uso della l-carnitina per il trattamento di patologie cardiovascolari. - Google Patents

Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Info

Publication number
ITRM20040346A1
ITRM20040346A1 IT000346A ITRM20040346A ITRM20040346A1 IT RM20040346 A1 ITRM20040346 A1 IT RM20040346A1 IT 000346 A IT000346 A IT 000346A IT RM20040346 A ITRM20040346 A IT RM20040346A IT RM20040346 A1 ITRM20040346 A1 IT RM20040346A1
Authority
IT
Italy
Prior art keywords
carnitine
infarction
treatment
grams
days
Prior art date
Application number
IT000346A
Other languages
English (en)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000346A priority Critical patent/ITRM20040346A1/it
Publication of ITRM20040346A1 publication Critical patent/ITRM20040346A1/it
Priority to AT05755616T priority patent/ATE542529T1/de
Priority to EP05755616A priority patent/EP1773314B1/en
Priority to ES05755616T priority patent/ES2380913T3/es
Priority to HK08102916.9A priority patent/HK1113542B/xx
Priority to MEP-2012-32A priority patent/ME01345B/me
Priority to KR1020077000711A priority patent/KR101296479B1/ko
Priority to PT05755616T priority patent/PT1773314E/pt
Priority to PCT/EP2005/006657 priority patent/WO2006005415A2/en
Priority to SI200531481T priority patent/SI1773314T1/sl
Priority to US11/629,202 priority patent/US7879908B2/en
Priority to RS20120095A priority patent/RS52253B/en
Priority to CA2569888A priority patent/CA2569888C/en
Priority to BRPI0513303A priority patent/BRPI0513303A8/pt
Priority to PL05755616T priority patent/PL1773314T3/pl
Priority to AU2005262050A priority patent/AU2005262050B2/en
Priority to HRP20120178TT priority patent/HRP20120178T1/hr
Priority to JP2007520688A priority patent/JP5230195B2/ja
Priority to CN201110226409.1A priority patent/CN102349923B/zh
Priority to MXPA06014665A priority patent/MXPA06014665A/es
Priority to CN2005800234751A priority patent/CN101087602B/zh
Priority to DK05755616.9T priority patent/DK1773314T3/da
Priority to US12/972,617 priority patent/US8394854B2/en
Priority to CY20121100341T priority patent/CY1112686T1/el
Priority to HK12106717.5A priority patent/HK1166003B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT000346A 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari. ITRM20040346A1 (it)

Priority Applications (25)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
DK05755616.9T DK1773314T3 (da) 2004-07-13 2005-06-21 Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme
US11/629,202 US7879908B2 (en) 2004-07-13 2005-06-21 Use of L-carnitine for the treatment of cardiovascular diseases
CA2569888A CA2569888C (en) 2004-07-13 2005-06-21 Use of l-carnitine for the treatment of cardiovascular diseases
ES05755616T ES2380913T3 (es) 2004-07-13 2005-06-21 Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares
HK08102916.9A HK1113542B (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases
MEP-2012-32A ME01345B (me) 2004-07-13 2005-06-21 Upotreba l-karnitina za liječenje kardiovaskularnih bolesti
KR1020077000711A KR101296479B1 (ko) 2004-07-13 2005-06-21 심혈관 질환 치료를 위한 ｌ-카르니틴 및 글루코오스의용도
PT05755616T PT1773314E (pt) 2004-07-13 2005-06-21 Uso de l-carnitina para o tratamento de doenças cardiovasculares
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases
SI200531481T SI1773314T1 (sl) 2004-07-13 2005-06-21 Uporaba L-karnitina za zdravljenje kardiovaskularnih bolezni
AT05755616T ATE542529T1 (de) 2004-07-13 2005-06-21 Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen
RS20120095A RS52253B (en) 2004-07-13 2005-06-21 USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP05755616A EP1773314B1 (en) 2004-07-13 2005-06-21 Use of l-carnitine for the treatment of cardiovascular diseases
BRPI0513303A BRPI0513303A8 (pt) 2004-07-13 2005-06-21 Uso de l-carnitina para o tratamento de doenças cardiovasculares
PL05755616T PL1773314T3 (pl) 2004-07-13 2005-06-21 Zastosowanie L-karnityny do leczenia chorób naczyniowo-sercowych
AU2005262050A AU2005262050B2 (en) 2004-07-13 2005-06-21 Use of L-carnitine and glucose for the treatment of cardiovascular diseases
HRP20120178TT HRP20120178T1 (hr) 2004-07-13 2005-06-21 Upotreba l-karnitina u liječenju kardiovaskularnih bolesti
JP2007520688A JP5230195B2 (ja) 2004-07-13 2005-06-21 心血管疾患の治療のためのｌ−カルニチンおよびグルコースの使用
CN201110226409.1A CN102349923B (zh) 2004-07-13 2005-06-21 L-肉碱和葡萄糖治疗心血管疾病的应用
MXPA06014665A MXPA06014665A (es) 2004-07-13 2005-06-21 Uso de l-carnitina y glucosa para el tratamiento de enfermedades cardiovasculares.
CN2005800234751A CN101087602B (zh) 2004-07-13 2005-06-21 L-肉碱和葡萄糖治疗心血管疾病的应用
US12/972,617 US8394854B2 (en) 2004-07-13 2010-12-20 Use of L-carnitine for the treatment of cardiovascular diseases
CY20121100341T CY1112686T1 (el) 2004-07-13 2012-04-05 Χρηση l-καρνιτινης για τη θεραπεια καρδιαγγειακων νοσηματων
HK12106717.5A HK1166003B (en) 2004-07-13 2012-07-10 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Publications (1)

Publication Number Publication Date
ITRM20040346A1 true ITRM20040346A1 (it) 2004-10-13

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Country Status (21)

Country Link
US (2) US7879908B2 (it)
EP (1) EP1773314B1 (it)
JP (1) JP5230195B2 (it)
KR (1) KR101296479B1 (it)
CN (2) CN101087602B (it)
AT (1) ATE542529T1 (it)
AU (1) AU2005262050B2 (it)
BR (1) BRPI0513303A8 (it)
CA (1) CA2569888C (it)
CY (1) CY1112686T1 (it)
DK (1) DK1773314T3 (it)
ES (1) ES2380913T3 (it)
HR (1) HRP20120178T1 (it)
IT (1) ITRM20040346A1 (it)
ME (1) ME01345B (it)
MX (1) MXPA06014665A (it)
PL (1) PL1773314T3 (it)
PT (1) PT1773314E (it)
RS (1) RS52253B (it)
SI (1) SI1773314T1 (it)
WO (1) WO2006005415A2 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
CA2352485A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
CZ303870B6 (cs) * 1999-10-11 2013-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. Vyuzití L-karnitinu a jeho alkanoylderivátu jako osmotických prostredku v roztocích pro medicinální vyuzití
JP4674046B2 (ja) * 2002-04-01 2011-04-20 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ グルコース利用を刺激する化合物および使用方法
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
AU2005262050B2 (en) 2011-02-24
HRP20120178T1 (hr) 2012-05-31
JP2008517872A (ja) 2008-05-29
CN101087602B (zh) 2011-09-14
AU2005262050A1 (en) 2006-01-19
WO2006005415A2 (en) 2006-01-19
US20070207970A1 (en) 2007-09-06
ES2380913T3 (es) 2012-05-21
HK1166003A1 (zh) 2012-10-19
KR20070039541A (ko) 2007-04-12
JP5230195B2 (ja) 2013-07-10
HK1113542A1 (en) 2008-10-10
CN102349923A (zh) 2012-02-15
EP1773314A2 (en) 2007-04-18
EP1773314B1 (en) 2012-01-25
US7879908B2 (en) 2011-02-01
ME01345B (me) 2012-10-31
WO2006005415A3 (en) 2006-05-26
ATE542529T1 (de) 2012-02-15
KR101296479B1 (ko) 2013-08-13
US8394854B2 (en) 2013-03-12
CN101087602A (zh) 2007-12-12
BRPI0513303A8 (pt) 2017-12-26
CY1112686T1 (el) 2016-02-10
CA2569888A1 (en) 2006-01-19
US20110086917A1 (en) 2011-04-14
PT1773314E (pt) 2012-03-29
RS52253B (en) 2012-10-31
DK1773314T3 (da) 2012-05-07
PL1773314T3 (pl) 2012-06-29
BRPI0513303A (pt) 2008-05-06
CN102349923B (zh) 2016-04-27
MXPA06014665A (es) 2007-03-12
SI1773314T1 (sl) 2012-04-30
CA2569888C (en) 2013-08-13

Similar Documents

Publication Publication Date Title
Ravin et al. Fatal cardiac event following initiation of risperidone therapy
Jaspan et al. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function
ES2577930T3 (es) Derivados de triazina para retrasar el inicio de la diabetes tipo 1
FI3628319T3 (fi) Hepaattisen enkefalopatian hoito rifaksimiinilla
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
Milavec-Puretić et al. Drug induced psoriasis
CA2593171A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
JP7208139B2 (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
CY1112686T1 (el) Χρηση l-καρνιτινης για τη θεραπεια καρδιαγγειακων νοσηματων
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
Poole-Wilson Timolol maleate (MK 950) in the treatment of essential hypertension
Prabhu et al. Digital gangrene due to dopamine infusion-a case report
CY1114250T1 (el) Ακετυλ l-καρνιτινη για την προληψη της επιπονης περιφερικης διαβητικης νευροπαθειας
JP2008517872A5 (it)
UA70535A (en) Method for preventing paroxysms of atrial fibrillamethod for preventing paroxysms of atrial fibrillation in ischemic disease of heart in elderly tion in ischemic disease of heart in elderly
ITRM20010695A1 (it) Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del